When Will We Have A Pill To Treat Covid? Here Are Three Antiviral Drugs Being Tested
Merck said molnupiravir, the antiviral drug it’s developing with Miami-based Ridgeback Biotherapeutics, could halve the risks of hospitalization or death when given to recently diagnosed patients at risk of severe illness, according to interim results from a late-stage clinical trial. If approved, molnupiravir would be the first antiviral pill for Covid-19 on the market and become a valuable tool in the fight against the virus.
Rivals are not far behind, with Pfizer, Roche and Atea Pharmaceuticals all expecting results from late-stage clinical trials this year.